Description: Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Home Page: www.synairgen.com
Mailpoint 810
Southampton,
SO16 6YD
United Kingdom
Phone:
44 23 8051 2800
Officers
| Name | Title |
|---|---|
| Mr. Richard Marsden | CEO, MD & Executive Director |
| Prof. Stephen T. Holgate CBE, M.D. | Co-Founder, Non-Executive Director & Member of Scientific Advisory Board |
| Mr. Joseph Tregonning Colliver F.C.A. | CFO & Executive Director |
| Dr. Phillip David Monk | Chairman of Scientific Advisory Board, Chief Scientific Officer & Executive Director |
| Prof. Donna Davies | Co-Founder & Member of Scientific Advisory Board |
| Prof. Ratko Djukanovic | Co-Founder & Member of Scientific Advisory Board |
| Dr. Gareth E. Walters Ph.D. | Chief Regulatory Officer |
| Ms. Jody Brookes | Senior VP & Head of Clinical Operations |
| Mr. Richard Francis | Senior VP and Head of CMC & Quality |
| Dr. Victoria Tear | Head of Laboratory |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4396 |
| Price-to-Sales TTM: | 699.7328 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 36 |